

677 Ala Moana Blvd., Suite 404, Honolulu, HI 96813-5412

			PRESCRIBER INFORMATION	expedite prescription fulfillment.
Fo	our simple steps to s	ubmit your referral.	Date Time Date medic	ation needed
1 PATIENT INFORMATION New patient Current			Prescriber's first name Last name Prescriber's title	
			If NP or PA, under direction of Dr	
Patient first name			Office contact and title	
Last name Middle initial			Office contact email	
Date of birth			Office/clinic/institution name	
Street address Apt # City State Zip			Clinic/hospital affiliation	
City State Zip			Street address S	Suite #
Parent/guardian (if applicable)			City S	tate Zip
Home phone			Phone	Fax
Evening phone E-mail address			NPI #	License #
Patient's primary language: ☐ English ☐ Other If other, please specify			Deliver product to: ☐ Hospital ☐ Clinic	
If this order is for a pre-natally diagnosed infant, please include:			Shipping address	
Mother's name	SSNExpecte	nd infant delivery date	3 CLINICAL INFORMATION	
			1 2 45 45	te of Dx
Please attach copies	of front and back of patient's	insurance cards or complete information below.	SMA Type: 🔲 🗎 🗎 🗎 🗎 Other	
Insurance company			Is diagnosis confirmed by genetic testing? Yes No	
Phone			If yes, please include copies of all available results of genetic analysis.	
Insured's name			Plan authorization may require one or more of the following: (please attach if available)	
Insured's employer Relationship to patient			· Genetic confirmation of SMN-1 deletion or mutation status	
Identification # Policy/group #			Documented parental carrier status or prenatal testing	
Prescription card: Yes No If yes, carrier			Documented family history of 5qSMA SAN 3 constitutions and bridge statements and bridge statements are sensitive and bridge statements.	
Policy # Group #			SMN-2 genetic analysis Chart note indicating patient status or response to therapy	
Is patient eligible for Medicare? \(\text{Yes} \) No			SCr Date	
Does patient have a secondary insurance? ☐ Yes ☐ No			□ NKDA □ Known drug allergies	
)			Concurrent meds	
4 PRESCR	IBING INFORMA	TION		
Medication	Strength/Formulation	Directions		Quantity/Refills
□ Spinraza	12mg/5mL vial	Administer 12mg intrathecally via sterile	procedure as per product instructions according to the followin	g Dispense:
(nusinersen)		schedule (enter dates to be given):		☐ Up to 28 days supply for
		□ Loading dose 1: □ Already given in hospital/clinic □ Loading dose 2 (14 days after loading dose 1): □ Already given in hospital/clinic □ Loading dose 3 (14 days after loading dose 2): □ Already given in hospital/clinic		loading or 1 maintenance
				administration
				☐ Other
				Refills
		☐ Loading dose 4 (30 days after loading o ☐ Already given in hospital/clinic	dose 3):	
			the affect 4th leading does Newtiniontics date	
		□ Maintenance dose given every 4 months after 4 th loading dose: Next injection date		
		Other instructions	-	
				-
If shipped to physicis		n behalf of patient for administration in office.		_
By signing below, I certify that the above therapy is medically necessary. I also authorize Accredo to initiate any de minimus authorization processes from applicable health plans, if needed, including				
Prescriber's signature (sign below) (Physician attests this is his/her legal signature. NO STAMPS) PHYSICIAN SIGNATURE REQUIRED				
 Date	 Dispense as written		Date Substitution allowed	
Pate	DISPENSE AS WITHER		Date Substitution anowed	

Please fax completed form to your team at 808.650.6487. To reach your team, call toll-free 808.650.6488. You can now monitor shipments and chat online if you have questions. Go to MyAccredoPatients.com to log in or get started.

The prescriber is to comply with his/her state-specific prescription requirements such as e-prescribing, state-specific prescription form, fax language, etc. Non-compliance with state-specific requirements could result in outreach to the prescriber.

The document(s) accompanying this transmission may contain confidential health information that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party unless required to do so by law or regulation. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately and arrange for the return or destruction of these documents.